Phase 3 trial in cardiovascular and kidney disease indications
Latest Information Update: 18 Oct 2023
At a glance
- Drugs Ocedurenone (Primary)
- Indications Cardiovascular disorders; Kidney disorders
- Focus Therapeutic Use
- 18 Oct 2023 New trial record
- 16 Oct 2023 According to a Novo Nordisk media release, company expects to initiate phase 3 trials in additional cardiovascular and kidney disease indications in the coming years.